clinical trial · NCT06672978
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)·phase2·recruiting·n = 66
Acute PyelonephritisComplicated Urinary Tract InfectionMeropenem-VaborbactamAntibiotics
brief summary
The primary objective of the study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP).
started
Jun 3, 2025
primary completion
Jan 1, 2027
completion
Jul 1, 2027
last updated
Dec 17, 2025
official title
A Multi-Center, Open-Label, Single-Arm, Phase 2 Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Vabomere (Meropenem-Vaborbactam) In The Treatment Of Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol